These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23515098)

  • 1. In focus: MLL-rearranged leukemia.
    de Boer J; Walf-Vorderwülbecke V; Williams O
    Leukemia; 2013 Jun; 27(6):1224-8. PubMed ID: 23515098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting epigenetic programs in MLL-rearranged leukemias.
    Bernt KM; Armstrong SA
    Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic strategies for MLL-rearranged leukemias.
    Wong NM; So CWE
    Biochim Biophys Acta Gene Regul Mech; 2020 Sep; 1863(9):194584. PubMed ID: 32534041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MLL-rearranged leukemias: insights from gene expression profiling.
    Armstrong SA; Golub TR; Korsmeyer SJ
    Semin Hematol; 2003 Oct; 40(4):268-73. PubMed ID: 14582077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.
    Li BE; Ernst P
    Exp Hematol; 2014 Dec; 42(12):995-1012. PubMed ID: 25264566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When epigenetics kills: MLL fusion proteins in leukemia.
    Slany RK
    Hematol Oncol; 2005 Mar; 23(1):1-9. PubMed ID: 16118769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent
    Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
    Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for DOT1L in MLL-rearranged leukemias.
    Bernt KM; Armstrong SA
    Epigenomics; 2011 Dec; 3(6):667-70. PubMed ID: 22126283
    [No Abstract]   [Full Text] [Related]  

  • 14. PAFc, a key player in MLL-rearranged leukemogenesis.
    Tan J; Muntean AG; Hess JL
    Oncotarget; 2010 Oct; 1(6):461-5. PubMed ID: 21037944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs mark in the MLL-rearranged leukemia.
    Benetatos L; Vartholomatos G
    Ann Hematol; 2013 Nov; 92(11):1439-50. PubMed ID: 23728610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias.
    Li Z; Luo RT; Mi S; Sun M; Chen P; Bao J; Neilly MB; Jayathilaka N; Johnson DS; Wang L; Lavau C; Zhang Y; Tseng C; Zhang X; Wang J; Yu J; Yang H; Wang SM; Rowley JD; Chen J; Thirman MJ
    Cancer Res; 2009 Feb; 69(3):1109-16. PubMed ID: 19155294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of leukemogenesis by MLL fusion proteins.
    Marschalek R
    Br J Haematol; 2011 Jan; 152(2):141-54. PubMed ID: 21118195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements.
    Nishi M; Eguchi-Ishimae M; Wu Z; Gao W; Iwabuki H; Kawakami S; Tauchi H; Inukai T; Sugita K; Hamasaki Y; Ishii E; Eguchi M
    Leukemia; 2013 Feb; 27(2):389-97. PubMed ID: 22918121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of MLL-associated leukemia.
    Yokoyama A
    Int J Hematol; 2015 Apr; 101(4):352-61. PubMed ID: 25773519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
    Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
    J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.